研究人员发现，维替泊芬通过靶向内皮细胞中的 YAP/TAZ 通路激活来减少 HGPS 小鼠的动脉粥样硬化。 Researchers discover verteporfin reduces atherosclerosis in HGPS mice by targeting YAP/TAZ pathway activation in endothelial cells.

研究人员指出,在Hutchinson-Gilford progeria综合症(HGPS)中,内皮细胞中的YAP/TAZ途径的激活是发展无神体硬化症的一个关键因素,这是一种罕见的遗传疾病,导致早期心血管疾病。 Researchers have pinpointed the YAP/TAZ pathway's activation in endothelial cells as a key factor in developing atherosclerosis in Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder leading to early cardiovascular disease. 使用维替泊芬（一种治疗年龄相关性黄斑变性的药物），他们观察到 HGPS 小鼠的动脉粥样硬化显着减少。 Using verteporfin, a drug for age-related macular degeneration, they observed significant reductions in atherosclerosis in HGPS mice. 这一发现可能为HGPS和其他与年龄有关的心血管疾病的新治疗铺平道路,尽管还需要进一步研究。 This discovery may pave the way for new treatments for HGPS and other age-related cardiovascular conditions, though further research is necessary.